TherapeuticsMD Inc (TXMD)
Official siteHEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NASDAQ
Market Cap: $20.95M
Last updated: Nov 17, 2026 at 4:10 PM ET
TherapeuticsMD Inc (TXMD) Stock Chart
TherapeuticsMD (TXMD) has a latest price of $1.91 on Nov 17, 2026, 35.3% below its 52-week high of $2.95. Its price fell 2.6% over the past 12 months. The month-end price fell 99.4% over the 10 years through Oct 2026, a compound annual decline of 39.8%.
Price Chart
From Oct 2016 to Oct 2026, its highest month-end close was $360.00 in Mar 2017 and its lowest $0.86 in Dec 2024, adjusted for splits.
Month-end closes, adjusted for splits. Dividends are not included.
Chart TXMD with Advanced Charting
Daily candlesticks, valuation multiples, side-by-side comparisons and drawings for TXMD.
Free with a GNG account. No credit card.
Price Performance
Over the past 3 months the price fell 5.9%, and over 6 months it fell 6.4%. The month-end price fell 15.5% over the 3 years through Oct 2026, a compound annual decline of 5.5%.
| Period | Change |
|---|---|
| 1 month | +2.7% |
| 3 months | -5.9% |
| 6 months | -6.4% |
| 12 months | -2.6% |
| 12 months, with dividends | -2.6% |
| Period | Change | Per year |
|---|---|---|
| 3 years | -15.5% | -5.5% |
| 5 years | -95.1% | -45.2% |
| 10 years | -99.4% | -39.8% |
Price by Year
Its best calendar year was 2025, when the price rose 89.5%, and its weakest was 2021, when it fell 70.6%.
| Year | Close | Change |
|---|---|---|
| 2026 through Oct 2026 | $1.80 | +10.4% |
| 2025 | $1.63 | +89.5% |
| 2024 | $0.86 | -61.8% |
| 2023 | $2.25 | -59.7% |
| 2022 | $5.59 | -68.6% |
| 2021 | $17.77 | -70.6% |
| 2020 | $60.50 | -50.0% |
| 2019 | $121.00 | -36.5% |
| 2018 | $190.50 | -36.9% |
| 2017 | $302.00 | +4.7% |
Trading Range
The price is 2.4% below its 50-day average of $1.96 and 8.2% below its 200-day average of $2.08.
| Measure | Value | Price vs |
|---|---|---|
| Latest price (Nov 17, 2026) | $1.91 | |
| 52-week high | $2.95 | -35.3% |
| 52-week low | $1.43 | +33.6% |
| 50-day average | $1.96 | -2.4% |
| 200-day average | $2.08 | -8.2% |
Price Risk
Over 3 years, its largest fall from a peak was 75.6%.
| Measure | Value |
|---|---|
| 1-year beta | 0.28 |
| Largest fall, 1 year | -39.0% |
| Largest fall, 3 years | -75.6% |
Advanced Charting Features
Advanced Charting is free with a GNG account, and signed-in members get it in place of the price chart above.
- Valuation multiples. Daily P/E, price to sales, cash flow and book value, PEG and PEGY, drawn behind the price wherever the company's data supports them.
- Price charts and drawings. Candlestick, OHLC, line and area charts with volume and earnings, dividend and split markers, plus trend lines, levels and notes kept in your account.
- Side-by-side compare. Two stocks next to each other on one metric and time span, each chart with its own price scale.
- Projections and saved views. Pick a start and an end point to see the price return, dividends and total return between them, and save views to open later.
Frequently Asked Questions About TXMD
What is TXMD's 1-year price change?
TherapeuticsMD's price fell 2.6% over the past 12 months. With dividends included, the 12-month total return was -2.6%.
What is TXMD's 5-year price change?
TherapeuticsMD's month-end price fell 95.1% over the 5 years through Oct 2026, a compound annual decline of 45.2%. These figures leave out dividends.
What is TXMD's 52-week high and low?
TherapeuticsMD's 52-week high is $2.95 and its 52-week low is $1.43. Its latest price of $1.91 on Nov 17, 2026 is 35.3% below the high.
What is TXMD's beta?
TherapeuticsMD's 1-year beta against the S&P 500 is 0.28, so its price has moved less than the market over the past year. Its largest fall from a peak over the past year was 39.0%.
Is the TXMD chart free?
Yes. Advanced Charting for TXMD is free with a GNG account, and no credit card is needed. It adds daily candlestick and line charts with volume, valuation multiples, side-by-side comparisons, drawings and saved views.
TXMD pages: Overview, Charting, Earnings, Financials, Statistics, Valuation, Competitors